Neuromeka Statistics
Total Valuation
Neuromeka has a market cap or net worth of KRW 253.40 billion. The enterprise value is 289.27 billion.
Market Cap | 253.40B |
Enterprise Value | 289.27B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Neuromeka has 11.34 million shares outstanding. The number of shares has increased by 1.54% in one year.
Current Share Class | 11.34M |
Shares Outstanding | 11.34M |
Shares Change (YoY) | +1.54% |
Shares Change (QoQ) | +2.75% |
Owned by Insiders (%) | 20.29% |
Owned by Institutions (%) | 2.03% |
Float | 9.04M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 10.22 |
PB Ratio | 11.01 |
P/TBV Ratio | 11.14 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -15.77 |
EV / Sales | 11.66 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.13 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 2.19.
Current Ratio | 0.91 |
Quick Ratio | 0.57 |
Debt / Equity | 2.19 |
Debt / EBITDA | n/a |
Debt / FCF | -1.24 |
Interest Coverage | -3.56 |
Financial Efficiency
Return on equity (ROE) is -88.36% and return on invested capital (ROIC) is -17.02%.
Return on Equity (ROE) | -88.36% |
Return on Assets (ROA) | -12.25% |
Return on Invested Capital (ROIC) | -17.02% |
Return on Capital Employed (ROCE) | -37.29% |
Revenue Per Employee | 174.67M |
Profits Per Employee | -129.21M |
Employee Count | 142 |
Asset Turnover | 0.27 |
Inventory Turnover | 3.33 |
Taxes
In the past 12 months, Neuromeka has paid 26.62 million in taxes.
Income Tax | 26.62M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.95% in the last 52 weeks. The beta is 0.98, so Neuromeka's price volatility has been similar to the market average.
Beta (5Y) | 0.98 |
52-Week Price Change | -26.95% |
50-Day Moving Average | 24,629.00 |
200-Day Moving Average | 25,360.70 |
Relative Strength Index (RSI) | 35.96 |
Average Volume (20 Days) | 50,503 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuromeka had revenue of KRW 24.80 billion and -18.35 billion in losses. Loss per share was -1,726.45.
Revenue | 24.80B |
Gross Profit | 3.83B |
Operating Income | -18.18B |
Pretax Income | -18.32B |
Net Income | -18.35B |
EBITDA | -15.75B |
EBIT | -18.18B |
Loss Per Share | -1,726.45 |
Balance Sheet
The company has 14.52 billion in cash and 50.39 billion in debt, giving a net cash position of -35.87 billion or -3,164.14 per share.
Cash & Cash Equivalents | 14.52B |
Total Debt | 50.39B |
Net Cash | -35.87B |
Net Cash Per Share | -3,164.14 |
Equity (Book Value) | 23.01B |
Book Value Per Share | 2,029.37 |
Working Capital | -4.21B |
Cash Flow
In the last 12 months, operating cash flow was -26.79 billion and capital expenditures -13.78 billion, giving a free cash flow of -40.56 billion.
Operating Cash Flow | -26.79B |
Capital Expenditures | -13.78B |
Free Cash Flow | -40.56B |
FCF Per Share | -3,577.77 |
Margins
Gross margin is 15.44%, with operating and profit margins of -73.31% and -73.97%.
Gross Margin | 15.44% |
Operating Margin | -73.31% |
Pretax Margin | -73.87% |
Profit Margin | -73.97% |
EBITDA Margin | -63.52% |
EBIT Margin | -73.31% |
FCF Margin | n/a |
Dividends & Yields
Neuromeka does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.54% |
Shareholder Yield | n/a |
Earnings Yield | -7.24% |
FCF Yield | -16.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Neuromeka has an Altman Z-Score of 1.28 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.28 |
Piotroski F-Score | 2 |